Helus Pharma director Lewis-Hall holds 100K shares

The reported equity interests distinguish directly held common shares and restricted share units from options held through Intelmed, LLC.

Rhea-AI Filing Summary

Helus Pharma Inc. director Freda C. Lewis-Hall reported 100,000 common shares held directly on October 13, 2026. She also reported options held by Intelmed, LLC, an entity she owns and controls, covering 25,000 common shares at a $5.99 exercise price. The options vest quarterly over two years beginning December 31, 2025, and expire October 1, 2035. Her reported direct holdings also include 25,000 restricted share units, each representing a right to one common share and vesting November 20, 2026.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Lewis-Hall Freda C

Role Director

Type	Security	Shares	Price	Value
holding	Options ("Right to Buy") F2, F1, F3	--	--	--
holding	Restricted Share Units F5, F4	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Options ("Right to Buy") — 25,000 contracts (Indirect, Held by Intelmed, LLC); Restricted Share Units — 25,000 contracts (Direct); Common Shares — 100,000 shares (Direct)

Footnotes (5)

1. F1. The options vest quarterly over two years, commencing on December 31, 2025.
2. F2. Converted from Canadian exercise price of C$8.39 using an exchange rate of C$1.40 = US$1.00.
3. F3. Intelmed, LLC is a limited liability company owned and controlled by the reporting person.
4. F4. The restricted share units ("RSUs") vest on November 20, 2026.
5. F5. Each RSU represents a right to receive one Issuer common share.

Key Figures

Common shares held directly: 100,000 common shares Common shares underlying options: 25,000 common shares Option exercise price: $5.99 per share +4 more

7 metrics

Common shares held directly 100,000 common shares Reported October 13, 2026

Common shares underlying options 25,000 common shares Options held by Intelmed, LLC

Option exercise price $5.99 per share Options covering common shares

Directly held restricted share units 25,000 units Each unit represents a right to receive one common share

Option vesting begins December 31, 2025 Options vest quarterly over two years

Restricted share units vest November 20, 2026 Directly held restricted share units

Option expiration October 1, 2035 Options held by Intelmed, LLC

Key Terms

Restricted Share Units, exercise price, vest quarterly

3 terms

Restricted Share Units financial

"Each RSU represents a right to receive one Issuer common share."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

exercise price financial

"Converted from Canadian exercise price of C$8.39"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest quarterly financial

"The options vest quarterly over two years"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Helus Pharma holdings did director Freda C. Lewis-Hall report?

Freda C. Lewis-Hall reported 100,000 common shares held directly, options through Intelmed, LLC covering 25,000 common shares, and 25,000 directly held restricted share units. Intelmed is owned and controlled by Lewis-Hall.

When do Freda C. Lewis-Hall's Helus Pharma options and restricted share units vest?

The options vest quarterly over two years beginning December 31, 2025, and expire October 1, 2035. The 25,000 restricted share units vest November 20, 2026; each represents a right to one common share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 01:49 PM EDT Accepted by SEC EDGAR 10/26/2026 - 01:49 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lewis-Hall Freda C

(Last) (First) (Middle)

C/O HELUS PHARMA INC.

100 KING STREET W., SUITE 5600

(Street)

TORONTO M5X 1C9

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/13/2026

3. Issuer Name and Ticker or Trading Symbol
Helus Pharma Inc. [ HELP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	100,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options ("Right to Buy")	(1)	10/01/2035	Common Shares	25,000	$5.99(2)	I	Held by Intelmed, LLC(3)
Restricted Share Units	(4)	(4)	Common Shares	25,000	(5)	D

Explanation of Responses:

1. The options vest quarterly over two years, commencing on December 31, 2025.

2. Converted from Canadian exercise price of C$8.39 using an exchange rate of C$1.40 = US$1.00.

3. Intelmed, LLC is a limited liability company owned and controlled by the reporting person.

4. The restricted share units ("RSUs") vest on November 20, 2026.

5. Each RSU represents a right to receive one Issuer common share.

	/s/ Freda Lewis-Hall	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)